Emergent BioSolutions

NYSE EBS · Gaithersburg, MD

Works in Cardiovascular · Genetic & rare · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Psychiatry · Renal & urogenital · Respiratory · Women's health

Emergent BioSolutions is a clinical trial sponsor based in Gaithersburg, MD, listed as NYSE EBS. It has 7 active clinical trials with 580 planned participants, across 12 therapeutic areas. Since 2021 it has completed 35 trials and stopped 5 early.

Trial track record · since 2021

7Active trials580 planned participants
35Completed21 with results posted
5Stopped early13% of finished trials

Financials · NYSE EBS

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 7 active trials

StageTrialStatus

Questions about Emergent BioSolutions

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-07.

Approve Suite is not affiliated with Emergent BioSolutions.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.